Add listing
    0
    Add listing

    BigOmics Analytics completes first tranche of funding round Verified listing Verified listing

    BigOmics Analytics completes first tranche of funding round Verified listing Verified listing

    • Wednesday, October 8, 2025 @ 12:00 am

    BigOmics Analytics, a Swiss bioinformatics company empowering scientists to analyze omics data with its intelligent tools, today announced the successful first tranche of next funding round, raising $1.6M. The round was backed by new investors Diffusion Capital Partners and business angels from the SICTIC network, alongside continued support from existing investors, including TiVentures.

    The new capital will fuel BigOmics’ mission to make omics and multi-omics data analysis faster, simpler, and more accessible for life scientists worldwide. BigOmics’ platform – Omics Playground – provides an intuitive cloud-based solution enabling researchers to explore, visualize, and interpret complex transcriptomics, proteomics, metabolomics and lipidomics datasets. It is a collaborative infrastructure that enables data scientists and biologists to interactively share insights, unify data in a single platform to eliminate silos, and ensure results that are both reproducible and robust.

    “Closing this round is a milestone for BigOmics and a strong validation of our vision. This investment allows us to accelerate product development, expand into new markets, and bring omics data analysis to every lab bench”, said Murat Akhmedov, co-founder and CEO of BigOmics Analytics. “We believe the future of life sciences lies in empowering researchers to analyze and interpret insights from their data directly and in real time”, said Ivo Kwee, CTO and co-founder of the company.

    BigOmics has built a global community of more than 6,000 researchers, and over 60 biotech & pharma companies and institutes use its platforms to streamline data discovery and accelerate insights in cancer research, neurodegenerative diseases, immunology and beyond.

    “With the explosion of omics data, tools that lower the barrier to analysis are crucial for the next wave of biomedical breakthroughs. We are excited to back their vision”, said Alper Karagöz, Partner at Diffusion Capital Partners. “BigOmics stands out as a category-defining company with the technology and team to become the go-to platform for omics data analysis”, said Lorenzo Leoni, Managing Partner at TiVentures.

    The funding will be used to expand product development and enhance AI-powered capabilities for deeper biological insights, increase customer success and serve a growing global user base, and scale infrastructure for enterprise and clinical applications.

    You may also be interested in